Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Holekamp N, Gentile B, Giocanti-Aurégan A, García-Layana A, Peto T, Viola F, Kertes PJ, Mirt M, Kotecha A, Lambert J, Lewis HB, Chi GC. Holekamp N, et al. Among authors: gentile b. Ophthalmic Res. 2024;67(1):311-321. doi: 10.1159/000538975. Epub 2024 Apr 29. Ophthalmic Res. 2024. PMID: 38679018 Free article.
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.
Viola F, Chi GC, Holekamp NM, Giocanti-Aurégan A, García-Layana A, Peto T, Kertes PJ, Mirt M, Kotecha A, Lambert J, Lewis HB, Gentile B. Viola F, et al. Among authors: gentile b. Ophthalmic Res. 2024;67(1):516-527. doi: 10.1159/000540390. Epub 2024 Aug 29. Ophthalmic Res. 2024. PMID: 39208778 Free article.
Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.
García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL, Danzig C, Paris LP, Mirt M, Henry-Szatkowski M, Lewis HB, Gentile B. García-Layana A, et al. Among authors: gentile b. Ophthalmic Res. 2025;68(1):13-22. doi: 10.1159/000541349. Epub 2024 Nov 21. Ophthalmic Res. 2025. PMID: 39571557 Free article.
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee Y, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. Scheinberg P, et al. Among authors: gentile b. Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25. Am J Hematol. 2024. PMID: 38924124 Clinical Trial.
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Röth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, Lee JH, Brodsky A, Hantaweepant C, Dumagay TE, Demichelis-Gómez R, Rojnuckarin P, Sun J, Höglund M, Jang JH, Gaya A, Silva F, Obara N, Kelly RJ, Beveridge L, Buatois S, Chebon S, Gentile B, Lundberg P, Sreckovic S, Nishimura JI, Risitano A, Han B. Röth A, et al. Among authors: gentile b. Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17. Am J Hematol. 2024. PMID: 38884175 Clinical Trial.
141 results